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Purpose of the study
Aim of the ADONE study was to verify the effect of a
reduced number of pills on adherence and HAART accept-
ability.
Methods
ADONE is a prospective, multicenter study in patients
chronically treated with FTC+TDF+EFV or 3TC+TDF+EFV,
showing a stable viremia <50 copies/ml. At baseline,
patients substituted their HAART with a fixed-dose combi-
nation (FDC) of FTC+TDF+EFV. Data were collected by
means of a modified ACTG questionnaire. To collect the
answers a visual analogue scale based on a horizontal line
of 100 mm was used. For each item patients were asked to
scale themselves from 0–100. The study is ongoing and
planned to complete 6-months follow-up. A planned pre-
liminary analysis according to the intention-to-treat
approach is reported.
Summary of results
A total of 203 patients (159 males and 44 females) with a
mean age of 46.3 years (SD 10.0) were enrolled. At base-
line all patients had a viral load below the limit of detec-
tion and the mean CD4 count was 564 cells/mcL (SD
250). The simple reduction of the number of pills,
induced a statistically significant (p = 0.014) increment of
self-reported adherence (number of doses assumed over
the previous month) from the mean baseline value of
96.1% (95% CI 94.3–97.9) to 97.7% (95% CI
97.0–98.4). Similarly the number of doses assumed ful-
filling scheduled timing (+/- 1 hour) increased from
92.9% (95% CI 90.4–95.4) to 96.0% (95% CI 94.8–97.2)
(p = 0.033). A marked increment of treatment acceptabil-
ity (p < 0.0001 for all items) was also observed after ther-
apeutic switch (Figure 1). All patients maintained HIV-
RNA <50 copies/ml.
Conclusion
The ADONE study is the first clinical experience exploring
the effect on adherence of a simplification strategy based
on the reduction of pills without a substantial change of
the drugs included into the therapeutic regimen. Its pri-
mary endpoints are adherence, acceptability of HAART
and quality of life of patients. By simply using a FDC, one
pill once-a-day, we obtained an improvement of self-
reported adherence. Furthermore, the patients' judgement
about simplicity, convenience, tolerability and efficacy of
the FDC was significantly more positive if compared with
the use of the same drugs as single pills. The simplicity of
the therapeutic regimen is an added value of HAART that
increments adherence and may improve long-term suc-
cess.
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